About Contact Us Careers

Renin Inhibitor Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 2633
Published Date: Oct 15, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Renin Inhibitor Landscape

Johnson & Johnson
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Pfizer
Bio-Rad Laboratories Inc.
Sanofi
Lupin
Merck & Co.
Astra Zeneca
Daiichi Sankyo
Novartis
Boehringer Ingelheim International GmbH

Browse Key Market Insights with Data Illustration:

Renin Inhibitor Market Size & Share, Growth Forecast 2036

In the News

September 2020: Aliskiren becomes the first direct renin inhibitor to available in the UK launched by Novartis and is licensed either as monotherapy or in combination with other antihypertensives.

Author Credits: Radhika Pawar

Report ID: 2633
Published Date: Oct 15, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Renin Inhibitor Market size is likely to expand at more than 6.6% CAGR during the forecast period i.e., between 2024-2036.

North America industry is set to account for largest revenue share by 2036, on account of a rise in the prevalence of hypertension and chronic kidney disorders.

The major players in the market are Johnson & Johnson, Pfizer, Bio-Rad Laboratories Inc., Sanofi, Lupin, Merck & Co., Astra Zeneca, Daiichi Sankyo, Novartis, Boehringer Ingelheim International GmbH, and others.

Inquiry Before Buying Request Free Sample